PPARG and lung carcinoma: Several studies have demonstrated that PPARγ activation can inhibit activation of NF-κB in NSCLC [43, 44].While effects on HIF-1 have not been documented in lung cancer cells,PPARγ has been shown to inhibit HIF-1 in other systems [45].